KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Liabilities and Shareholders Equity (2018 - 2025)

Vir Biotechnology's Liabilities and Shareholders Equity history spans 8 years, with the latest figure at $1.0 billion for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 28.31% to $1.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.5 billion, a 28.9% decrease, with the full-year FY2025 number at $1.0 billion, down 28.31% from a year prior.
  • Liabilities and Shareholders Equity hit $1.0 billion in Q4 2025 for Vir Biotechnology, down from $1.0 billion in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for VIR hit a ceiling of $2.9 billion in Q1 2022 and a floor of $1.0 billion in Q4 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $1.8 billion across 5 years, with a median of $1.7 billion in 2024.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 154.24% in 2022 and later crashed 32.71% in 2024.
  • Tracing VIR's Liabilities and Shareholders Equity over 5 years: stood at $2.0 billion in 2021, then soared by 43.38% to $2.8 billion in 2022, then plummeted by 31.51% to $1.9 billion in 2023, then dropped by 27.11% to $1.4 billion in 2024, then decreased by 28.31% to $1.0 billion in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for VIR at $1.0 billion in Q4 2025, $1.0 billion in Q3 2025, and $1.2 billion in Q2 2025.